Switch theme
Sign up to access all valuation multiples
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
n/a
LTM Revenue $5.6M
LTM EBITDA -$8.9M
$38.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Captor Therapeutics has a last 12-month revenue (LTM) of $5.6M and a last 12-month EBITDA of -$8.9M.
In the most recent fiscal year, Captor Therapeutics achieved revenue of $4.4M and an EBITDA of -$9.2M.
Captor Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Captor Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.6M | XXX | $4.4M | XXX | XXX | XXX |
| Gross Profit | $4.9M | XXX | $2.9M | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | -$8.9M | XXX | -$9.2M | XXX | XXX | XXX |
| EBITDA Margin | -160% | XXX | -208% | XXX | XXX | XXX |
| EBIT | -$10.4M | XXX | -$10.8M | XXX | XXX | XXX |
| EBIT Margin | -187% | XXX | -246% | XXX | XXX | XXX |
| Net Profit | -$10.2M | XXX | -$10.7M | XXX | XXX | XXX |
| Net Margin | -182% | XXX | -243% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Captor Therapeutics's stock price is PLN 35 (or $10).
Captor Therapeutics has current market cap of PLN 194M (or $53.8M), and EV of PLN 137M (or $38.0M).
See Captor Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $38.0M | $53.8M | XXX | XXX | XXX | XXX | $-1.98 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Captor Therapeutics has market cap of $53.8M and EV of $38.0M.
Captor Therapeutics's trades at 8.6x EV/Revenue multiple, and -4.1x EV/EBITDA.
Equity research analysts estimate Captor Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Captor Therapeutics has a P/E ratio of -5.3x.
See valuation multiples for Captor Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $53.8M | XXX | $53.8M | XXX | XXX | XXX |
| EV (current) | $38.0M | XXX | $38.0M | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | 8.6x | XXX | XXX | XXX |
| EV/EBITDA | -4.3x | XXX | -4.1x | XXX | XXX | XXX |
| EV/EBIT | -3.6x | XXX | -3.5x | XXX | XXX | XXX |
| EV/Gross Profit | 7.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.3x | XXX | -5.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCaptor Therapeutics's last 12 month revenue growth is 56%
Captor Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Captor Therapeutics's rule of 40 is -435% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Captor Therapeutics's rule of X is -20% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Captor Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 56% | XXX | 56% | XXX | XXX | XXX |
| EBITDA Margin | -160% | XXX | -208% | XXX | XXX | XXX |
| EBITDA Growth | -39% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -435% | XXX | -152% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -20% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 277% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 313% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Captor Therapeutics acquired XXX companies to date.
Last acquisition by Captor Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Captor Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Captor Therapeutics headquartered? | Captor Therapeutics is headquartered in Poland. |
| Is Captor Therapeutics publicy listed? | Yes, Captor Therapeutics is a public company listed on WAR. |
| What is the stock symbol of Captor Therapeutics? | Captor Therapeutics trades under CTX ticker. |
| When did Captor Therapeutics go public? | Captor Therapeutics went public in 2021. |
| Who are competitors of Captor Therapeutics? | Similar companies to Captor Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Captor Therapeutics? | Captor Therapeutics's current market cap is $53.8M |
| What is the current revenue of Captor Therapeutics? | Captor Therapeutics's last 12 months revenue is $5.6M. |
| What is the current revenue growth of Captor Therapeutics? | Captor Therapeutics revenue growth (NTM/LTM) is 56%. |
| What is the current EV/Revenue multiple of Captor Therapeutics? | Current revenue multiple of Captor Therapeutics is 6.8x. |
| Is Captor Therapeutics profitable? | Yes, Captor Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Captor Therapeutics? | Captor Therapeutics's last 12 months EBITDA is -$8.9M. |
| What is Captor Therapeutics's EBITDA margin? | Captor Therapeutics's last 12 months EBITDA margin is -160%. |
| What is the current EV/EBITDA multiple of Captor Therapeutics? | Current EBITDA multiple of Captor Therapeutics is -4.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
